FDA plans to restrict GLP-1 ingredients for compounders as Hims & Hers drops semaglutide pill

The FDA said on February 6, 2026 that it intends to restrict the active ingredients that go into compounded GLP-1 drugs marketed at mass scale as substitutes for approved products, citing quality and safety concerns and possible violations of federal law ^[1][3]. The Department of Health and Human Services said the same day that it would send Hims & Hers to the Justice Department for investigation ^[1][4].

The timing was immediate. Hims & Hers had put a compounded semaglutide pill on sale the day before, on February 5, at an introductory price of $49 a month, about $100 below Novo Nordisk's branded Wegovy pill ^[1]. On February 7 the telehealth company said it was backing out after talks with industry stakeholders, stating that "we have decided to stop offering access to this treatment" ^[1]. Hims & Hers did not answer a question about whether compounded semaglutide injections would stay on its site ^[1].

Novo Nordisk had threatened litigation before the pill went on sale, and on February 9 it filed a patent infringement suit against Hims & Hers ^[1][2][5]. The complaint points to U.S. Patent No. 8,129,343 and asks for a permanent injunction; Novo says mass compounding is occurring and that its patents are being infringed ^[2][5]. Eli Lilly, whose own weight-loss pill is expected in April, said through a spokesperson that "no one should be mass-compounding or selling knockoff GLP-1 products regardless of how they're administered" ^[1].

Investors moved fast: shares of Novo and Lilly sold off and then regained part of the loss, while Hims & Hers stock fell ^[1].

The agency's push covers more than ingredients. The FDA said it would target direct-to-consumer marketing that presents compounded products as generic versions or equivalents of approved drugs, or claims the same active ingredient or the same clinical results ^[3]. Companies that make, distribute or market unapproved compounded GLP-1s could face legal action without further notice, including seizure and injunction, the agency said ^[3][5]. That follows more than 55 warning letters sent on September 16, 2025 to online sellers over misleading advertising ^[5]. A separate warning letter to Boothwyn Pharmacy, dated January 16, 2026 and published February 10, cited insanitary conditions and products that did not match their stated strength, quality or purity ^[5].

Why it matters for patients

Compounded drugs are not FDA-approved, and the semaglutide pill Hims & Hers withdrew had not gone through clinical trials to show that it works ^[1][3]. The FDA has named specific hazards: reports of injectable compounded GLP-1s arriving warm or packed with too little ice, which can degrade the medicine, and products carrying false labels, including the names of licensed pharmacies that never made them ^[3]. The agency advises against using an injectable that arrives in that condition ^[3].

Cost and access are the other half of the picture. Compounded versions have drawn people whose insurance does not cover GLP-1s or who cannot afford list prices ^[3]. A federal pricing site that launched February 5 lists semaglutide tablets at $149 to $299 a month, semaglutide injections at $199 to $349, and tirzepatide injections at $299 to $449, against stated list prices of $1,349, $1,349 and $1,087 ^[5]. How long compounded GLP-1s remain widely available has not been reported.

What happens next

Novo Nordisk's once-daily semaglutide tablet reached the U.S. market in January 2026, and Lilly's pill is expected in April ^[1][2][5].

The shape of the ingredient restrictions is not yet known. Attorneys following the case have described possibilities that include adding foreign ingredient suppliers to a restricted list, more unannounced inspections, further warning letters or seizures, or a formal rule placing semaglutide on a "demonstrably difficult to compound" list; a proposed version of that rule has not been finalized ^[2]. Whether the Justice Department opens an investigation has not been disclosed ^[1].